India's homegrown Covid-19 vaccine has 78% efficacy against symptomatic infections, developer says
CNN
Pharmaceutical company Bharat Biotech announced it had concluded the final analysis of its Phase 3 clinical trials, which it called the largest Covid-19 vaccine trial in India.
The trial involved 25,800 participants aged 18 to 98. Of those, 2,433 people were over 60 years old, and 4,500 had comorbidities.
More Related News